Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

IVIEW Therapeutics

Request full access

Developing sustainable and innovative drugs to target unmet medical needs

Cranbury Township, United StatesFounded 2015Biotech & Life Sciences

About IVIEW Therapeutics

IVIEW Therapeutics Inc. is a clinical-stage biotechnology company, founded in late 2015, that is strategically positioned to address unmet needs within the ophthalmic therapeutics market. The company directs its resources toward developing treatments for a range of ocular diseases, including dry eye, infectious conjunctivitis, myopia, glaucoma, and presbyopia. As a clinical-stage entity, IVIEW's business model is centered on research and development, funded primarily through investments from stockholders, as it does not yet have approved products generating sales revenue. The company has successfully raised significant capital to advance its clinical programs, including an A++ financing round in January 2025.

The company was co-founded by Dr. Bo Liang and Dr. John J. Baldwin, both veterans of the pharmaceutical industry. Dr. Liang, the Chairman and CEO, is a serial entrepreneur with extensive experience in drug discovery. His previous success includes co-founding CLS Pharmaceuticals, whose lead asset was acquired by Shire for $300 million in 2015. Dr. Baldwin contributed 30 years to Merck, where he was instrumental in developing several medicines, including Trusopt for glaucoma. This deep industry experience underpins the company's strategy. Headquartered in Cranbury, New Jersey, IVIEW operates a research and development facility and also has a presence in China to support development in that market.

IVIEW's pipeline features several product candidates employing novel mechanisms and drug delivery platforms. A leading asset is IVW-1001, a TRPM8 agonist for dry eye disease, delivered via a differentiated ophthalmic eyelid wipe. This approach is designed to directly target receptors on the eyelid margin, differing from traditional eye drops. The company announced positive topline data from its Phase 1/2 trial for IVW-1001 in early 2025. Another key candidate is IVIEW-1201, a broad-spectrum antiseptic in-situ gel for acute conjunctivitis. This product uses a proprietary gel technology that allows for extended-release upon instillation in the eye. The company has completed Phase 2 trials for IVIEW-1201 and submitted a Phase 3 protocol to the FDA. The portfolio also includes a gene therapy project, IVW-2001, for glaucoma, which is expected to enter first-in-human trials.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
33.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2022 $25M $100M Undisclosed —
EARLY VCEquity / VC Mar 2021 $7M $28M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

IVIEW Therapeutics website traffic

Latest recorded traffic for IVIEW Therapeutics is 1.4K monthly website visits, up 180% over the last three months.

Latest monthly visits1.4K 3-month web change+180%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

IVIEW Therapeutics in the Cranbury Township ecosystem

Live from Dealroom

The IVIEW Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Other known investors2 additional known investors

Employees 9 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about IVIEW Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See IVIEW Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.